PARIS, Sept 12 - In July, Geneva Proteomics of Switzerland made a bold announcement, saying it planned to become the international leader in industrialized proteomics.

Armed with some of the leading brains in proteomics and $40 million in venture capital, the possibility that GeneProt would be able to conquer the market might have seemed feasible.

But on closer inspection many questions arise about how the company will achieve such an audacious goal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.